Marks LS - Search Results

1

Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease.

Linton HJ, Marks LS, Millar LS, Knott CL, Rittenhouse HG, Mikolajczyk SD. Linton HJ, et al. Among authors: marks ls. Clin Chem. 2003 Feb;49(2):253-9. doi: 10.1373/49.2.253. Clin Chem. 2003. PMID: 12560348

2

Free prostate-specific antigen in serum is becoming more complex.

Mikolajczyk SD, Marks LS, Partin AW, Rittenhouse HG. Mikolajczyk SD, et al. Among authors: marks ls. Urology. 2002 Jun;59(6):797-802. doi: 10.1016/s0090-4295(01)01605-3. Urology. 2002. PMID: 12031356 Review. No abstract available.

3

APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer.

Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, Cass M, Hodge P, Macairan ML, Marks LS, Rittenhouse H. Groskopf J, et al. Among authors: marks ls. Clin Chem. 2006 Jun;52(6):1089-95. doi: 10.1373/clinchem.2005.063289. Epub 2006 Apr 20. Clin Chem. 2006. PMID: 16627561

4

"BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia.

Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Wolfert RL, Marks LS, Song W, Wheeler TM, Slawin KM. Mikolajczyk SD, et al. Among authors: marks ls. Urology. 2000 Jan;55(1):41-5. doi: 10.1016/s0090-4295(99)00372-6. Urology. 2000. PMID: 10654892

5

A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue.

Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Marks LS, Song W, Wheeler TM, Slawin KM. Mikolajczyk SD, et al. Among authors: marks ls. Cancer Res. 2000 Feb 1;60(3):756-9. Cancer Res. 2000. PMID: 10676664

6

Seminal plasma contains "BPSA," a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia.

Mikolajczyk SD, Millar LS, Marker KM, Wang TJ, Rittenhouse HG, Marks LS, Slawin KM. Mikolajczyk SD, et al. Among authors: marks ls. Prostate. 2000 Nov 1;45(3):271-6. doi: 10.1002/1097-0045(20001101)45:3<271::aid-pros11>3.0.co;2-t. Prostate. 2000. PMID: 11074531

7

Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia.

Pannek J, Marks LS, Pearson JD, Rittenhouse HG, Chan DW, Shery ED, Gormley GJ, Subong EN, Kelley CA, Stoner E, Partin AW. Pannek J, et al. Among authors: marks ls. J Urol. 1998 Feb;159(2):449-53. doi: 10.1016/s0022-5347(01)63946-6. J Urol. 1998. PMID: 9649261 Clinical Trial.

8

Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissue.

Mikolajczyk SD, Millar LS, Marker KM, Rittenhouse HG, Wolfert RL, Marks LS, Charlesworth MC, Tindall DJ. Mikolajczyk SD, et al. Among authors: marks ls. Cancer Res. 1999 Aug 15;59(16):3927-30. Cancer Res. 1999. PMID: 10463585

9

PCA3: a molecular urine assay for predicting prostate biopsy outcome.

Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H, Groskopf J. Deras IL, et al. Among authors: marks ls. J Urol. 2008 Apr;179(4):1587-92. doi: 10.1016/j.juro.2007.11.038. Epub 2008 Mar 4. J Urol. 2008. PMID: 18295257 Clinical Trial.

10

Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia.

Marks LS, Dorey FJ, Rhodes T, Shery ED, Rittenhouse H, Partin AW, deKernion JB. Marks LS, et al. J Urol. 1996 Sep;156(3):1035-9. J Urol. 1996. PMID: 8709302

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

209 results

Search Page